share_log

NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

NeuroSense Therapeutics | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  04/05 09:33

Moomoo AI 已提取核心訊息

On April 5, 2024, NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced its financial results for the year ending December 31, 2023, and provided a business update. The company reported significant clinical results from its Phase 2b PARADIGM ALS trial, where its lead drug candidate, PrimeC, showed a 37.4% slower disease progression in ALS patients compared to placebo. The trial's positive outcomes extend to quality of life and complication-free survival, with plans to present the data at a medical conference and for publication. Financially, NeuroSense experienced an 18% increase in R&D expenses due to higher employee numbers and clinical program costs, while G&A expenses decreased by 20% primarily due to lower share-based compensation and insurance costs. Overall operating expenses slightly...Show More
On April 5, 2024, NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced its financial results for the year ending December 31, 2023, and provided a business update. The company reported significant clinical results from its Phase 2b PARADIGM ALS trial, where its lead drug candidate, PrimeC, showed a 37.4% slower disease progression in ALS patients compared to placebo. The trial's positive outcomes extend to quality of life and complication-free survival, with plans to present the data at a medical conference and for publication. Financially, NeuroSense experienced an 18% increase in R&D expenses due to higher employee numbers and clinical program costs, while G&A expenses decreased by 20% primarily due to lower share-based compensation and insurance costs. Overall operating expenses slightly decreased by 2%. As of year-end, the company had cash reserves of approximately $2.6 million. NeuroSense has filed its annual report on Form 20-F with the SEC, available on its investor relations website, and offers hard copies to shareholders upon request. The company continues to focus on developing treatments for ALS and other neurodegenerative diseases, with PrimeC having received Orphan Drug Designation in the U.S. and EU.
2024年4月5日,專注於神經退行性疾病的生物技術公司NeuroSense Therapeutics Ltd. 公佈了截至2023年12月31日的年度財務業績,並提供了業務最新情況。該公司報告了其2b期PARADIGM ALS試驗的顯著臨床結果,其主要候選藥物PrimeC顯示,與安慰劑相比,ALS患者的疾病進展減緩了37.4%。該試驗的積極結果延伸到生活質量和無併發症存活率,並計劃在醫學會議上公佈數據並發表。財務方面,由於員工人數和臨床項目成本的增加,NeuroSense的研發費用增長了18%,而併購費用下降了20%,這主要是由於基於股份的薪酬和保險成本降低。總體運營支出略有下降2%。截至年底...展開全部
2024年4月5日,專注於神經退行性疾病的生物技術公司NeuroSense Therapeutics Ltd. 公佈了截至2023年12月31日的年度財務業績,並提供了業務最新情況。該公司報告了其2b期PARADIGM ALS試驗的顯著臨床結果,其主要候選藥物PrimeC顯示,與安慰劑相比,ALS患者的疾病進展減緩了37.4%。該試驗的積極結果延伸到生活質量和無併發症存活率,並計劃在醫學會議上公佈數據並發表。財務方面,由於員工人數和臨床項目成本的增加,NeuroSense的研發費用增長了18%,而併購費用下降了20%,這主要是由於基於股份的薪酬和保險成本降低。總體運營支出略有下降2%。截至年底,該公司的現金儲備約爲260萬美元。NeuroSense已向美國證券交易委員會提交了20-F表格的年度報告,該報告可在其投資者關係網站上查閱,並應要求向股東提供硬拷貝。該公司繼續專注於開發肌萎縮性側索硬化症和其他神經退行性疾病的治療方法,PrimeC已在美國和歐盟獲得孤兒藥稱號。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息